Two Sigma Investments’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Two Sigma Investments's AVTX Position: Q3 2026 in Review
Two Sigma Investments reduced its Avalo Therapeutics (AVTX) stake by 28% in Q3 2026, selling an estimated $349K and leaving 48,137 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #3801.
Two Sigma Investments first reported a position in AVTX in Q2 2020 and has held it in 14 quarters since. The position peaked at $3.71M in Q2 2021. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Two Sigma Investments held 48,137 shares of Avalo Therapeutics worth $738K as of Q3 2026.
- Two Sigma Investments sold 18,957 Avalo Therapeutics shares in Q3 2026, an estimated $349K.
- Avalo Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #3801 holding.
- Two Sigma Investments first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 14 quarters since.
- Two Sigma Investments's Avalo Therapeutics position peaked at $3.71M in Q2 2021.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.